S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
S&P 500   3,325.05 (+0.25%)
DOW   29,343.50 (+0.16%)
QQQ   222.71 (+0.19%)
AAPL   316.35 (+0.35%)
FB   221.32 (-0.20%)
MSFT   166.12 (-0.03%)
AMZN   1,867.33 (-0.56%)
CGC   24.52 (+0.91%)
NVDA   248.12 (-0.33%)
MU   57.32 (-0.62%)
GE   11.79 (-0.42%)
TSLA   507.87 (-1.09%)
AMD   50.70 (+1.87%)
ACB   2.09 (-2.79%)
PRI   128.46 (+0.07%)
BAC   34.68 (-0.12%)
GILD   62.93 (-0.43%)
DIS   145.09 (-0.02%)
Log in

NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

$23.69
+0.03 (+0.13 %)
(As of 01/17/2020 12:39 PM ET)
Today's Range
$23.60
Now: $23.69
$23.76
50-Day Range
$22.39
MA: $23.32
$24.76
52-Week Range
$17.57
Now: $23.69
$24.82
Volume27,964 shs
Average Volume974,582 shs
Market Capitalization$16.29 billion
P/E Ratio20.25
Dividend Yield1.44%
Beta1.05
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRFS
CUSIPN/A
Phone212-969-3335

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.30 billion
Cash Flow$1.53 per share
Book Value$8.07 per share

Profitability

Net Income$704.63 million

Miscellaneous

Employees21,230
Market Cap$16.29 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.


GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

How were GRIFOLS S A/S's earnings last quarter?

GRIFOLS S A/S (NASDAQ:GRFS) posted its earnings results on Tuesday, October, 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.03. The biotechnology company earned $1.46 billion during the quarter, compared to analysts' expectations of $1.39 billion. GRIFOLS S A/S had a return on equity of 13.58% and a net margin of 11.12%. View GRIFOLS S A/S's Earnings History.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

5 brokerages have issued 12 month target prices for GRIFOLS S A/S's stock. Their forecasts range from $22.50 to $22.50. On average, they anticipate GRIFOLS S A/S's share price to reach $22.50 in the next year. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Media headlines about GRFS stock have been trending positive on Friday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for GRIFOLS S A/S.

Are investors shorting GRIFOLS S A/S?

GRIFOLS S A/S saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,290,000 shares, an increase of 37.6% from the December 15th total of 937,800 shares. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.5% of the company's stock are sold short. View GRIFOLS S A/S's Current Options Chain.

Who are some of GRIFOLS S A/S's key competitors?

What other stocks do shareholders of GRIFOLS S A/S own?

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Reilly Financial Advisors LLC (0.05%) and OLD National Bancorp IN (0.00%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including OLD National Bancorp IN.

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $23.69.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $16.29 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com/.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  692
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel